Neuropharmacology & Neurotherapeutics
Modafinil is indicated for the management of excessive daytime sleepiness associated with narcolepsy. The FDA has approved its use to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift-work sleep disorder. Although modafinil improves measures of sleepiness, it does not normalize them because it does not correct the basic underlying cause. Therefore, treatment may be required for an indefinite period.
Nov. 02, 2020